261 related articles for article (PubMed ID: 38087293)
1. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.
López de Sá A; Díaz-Tejeiro C; Poyatos-Racionero E; Nieto-Jiménez C; Paniagua-Herranz L; Sanvicente A; Calvo E; Pérez-Segura P; Moreno V; Moris F; Ocana A
J Hematol Oncol; 2023 Dec; 16(1):118. PubMed ID: 38087293
[TBL] [Abstract][Full Text] [Related]
2. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.
McCombs JR; Owen SC
AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608
[TBL] [Abstract][Full Text] [Related]
3. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
Singh D; Dheer D; Samykutty A; Shankar R
J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiologic and Pharmacologic Considerations to Improve the Design and Application of Antibody-Drug Conjugates.
Boghaert ER; Cox MC; Vaidya KS
Cancer Res; 2022 May; 82(10):1858-1869. PubMed ID: 35298624
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug Conjugates Containing Payloads from Marine Origin.
Cheng-Sánchez I; Moya-Utrera F; Porras-Alcalá C; López-Romero JM; Sarabia F
Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005497
[TBL] [Abstract][Full Text] [Related]
6. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
Lu J; Jiang F; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329
[TBL] [Abstract][Full Text] [Related]
7. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
12. Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease.
Pillow TH
Pharm Pat Anal; 2017 Jan; 6(1):25-33. PubMed ID: 28155578
[TBL] [Abstract][Full Text] [Related]
13. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C
Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286
[TBL] [Abstract][Full Text] [Related]
15. Trends in cancer-targeted antibody-drug conjugates.
Bidard FC; Trédan O
Target Oncol; 2014 Mar; 9(1):1-8. PubMed ID: 24221961
[TBL] [Abstract][Full Text] [Related]
16. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers.
Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R
Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
Malik P; Phipps C; Edginton A; Blay J
Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
[TBL] [Abstract][Full Text] [Related]
18. Stepping forward in antibody-drug conjugate development.
Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
[TBL] [Abstract][Full Text] [Related]
19. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
[TBL] [Abstract][Full Text] [Related]
20. Bystander effect of antibody-drug conjugates: fact or fiction?
Giugliano F; Corti C; Tarantino P; Michelini F; Curigliano G
Curr Oncol Rep; 2022 Jul; 24(7):809-817. PubMed ID: 35305211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
